Comment from Pediatric Inclusion Alliance
AnonymousSupportAdvocacy
Summary: The Pediatric Inclusion Alliance supports the draft guidance but urges the FDA to provide greater clarity on definitions like "individualized" and "well-characterized." They specifically advocate for more explicit language and flexibility regarding the early inclusion of children in clinical trials for rare diseases.
Please see attached comments from the Pediatric Inclusion Alliance.